Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viral Encephalitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Viral Encephalitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-004366-34 Sponsor Protocol Number: 311_FU2013 Start Date*: 2013-12-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: Neutralizing Antibody Titers 6 Years after the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection
    Medical condition: Study population: adult volunteers who received a booster dose of JE-VC in prestudy IC51-311, no specific medical condition is investigated, only antibody check.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015595-10 Sponsor Protocol Number: IC51-322 Start Date*: 2010-03-23
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022265-10 Sponsor Protocol Number: IC51-325 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: LONG TERM IMMUNITY AND SAFETY WITH OR WITHOUT A BOOSTER DOSE FOLLOWING PRIMARY VACCINATION WITH THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION IN A JEV-ENDEMIC COUNTRY. ...
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015588-15 Sponsor Protocol Number: IC51-323 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022266-27 Sponsor Protocol Number: IC51-324 Start Date*: 2010-12-13
    Sponsor Name:Valneva Austria GmbH
    Full Title: Long term immunity and safety following vaccination with the Japanese Encephalitis vaccine IC51 (IXIARO®, JESPECT®) in a pediatric population in non-endemic countries. Uncontrolled, Phase 3 Follow-...
    Medical condition: JE can be fatal or lead to long-term disability. Vaccination should therefore be considered for people who are at risk of exposure to JEV by travelling to endemic regions. The study within which no...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    17.0 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    17.0 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    17.0 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    17.0 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018630-52 Sponsor Protocol Number: IC51-315 Start Date*: 2010-05-27
    Sponsor Name:Intercell AG
    Full Title: AN OPEN-LABEL, UNCONTROLLED PHASE 4 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS (JE) VACCINE IXIARO® (IC51) IN AN ELDERLY POPULATION
    Medical condition: IXIARO® is used to protect adults against Japanese encephalitis (JE). JE can be fatal or lead to long-term disability. Vaccination with Ixiaro should be considered for people who are at risk of exp...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10014596 Encephalitis Japanese B LLT
    12.1 10023119 Japanese B encephalitis LLT
    12.1 10023120 Japanese B viral encephalitis LLT
    12.1 10023122 Japanese B virus encephalitis LLT
    12.1 10023123 Japanese encephalitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004634-24 Sponsor Protocol Number: IC51-314 Start Date*: 2008-09-18
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY OF A COMMERCIAL BATCH OF THE JAPANESE ENCEPHALITIS VACCINE IC51 UP TO TWENTY-FOUR MONTHS POST FILLING, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014596 Encephalitis Japanese B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005173-23 Sponsor Protocol Number: V49_23 Start Date*: 2012-03-08
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH
    Full Title: A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Differ...
    Medical condition: Safety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to health...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10037742 Rabies PT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10037743 Rabies viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001348-31 Sponsor Protocol Number: 2011-001348-31 Start Date*: 2011-05-31
    Sponsor Name:Mälarsjukhuset
    Full Title: Can the dosage of vaccine against TBE is optimized by means of changes in dosing interval for those over 50 years
    Medical condition: Tick-borne Encephalitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10043848 Tick-borne viral encephalitis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004892-36 Sponsor Protocol Number: SLE subcuvia 04 Sep 2006 Start Date*: 2007-03-15
    Sponsor Name:Department of Rheumatology,University hospital,Lund
    Full Title: An open randomized and comparative study on the efficacy and safety of additional treatment of subcutaneous immunoglobulin (Subcuvia) during cessation of Prednisolon in patients with active systemi...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040967 SLE LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000440-27 Sponsor Protocol Number: 690701 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxter AG
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: In this Study the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies after the First Booster and the Response to a Second Booster Vaccination with FSME-IMMUN 0.5ml in Adults will be ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020097-42 Sponsor Protocol Number: 701001 Start Date*: 2010-08-03
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years
    Medical condition: Evaluation of Immunogenicity of a TBE (Tick Borne Encephalitis) Vaccine in previously unvaccinated children aged 1 to below 15 years
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000810-35 Sponsor Protocol Number: TBE-Ped-Accel-01 Start Date*: 2007-04-19
    Sponsor Name:BIOVOMED
    Full Title: Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 Years
    Medical condition: Prevention of Tick-born encephalitis (TBE). The rapid immunization schedule recommended in the current SPC for FSME-IMMUN 0.5 ml (Day 0, Day 14) has been used in Austria for 20 years. FSME-IMMUN 0....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001676-21 Sponsor Protocol Number: V48P7E1 Start Date*: 2006-08-14
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants...
    Medical condition: TBE prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004457-40 Sponsor Protocol Number: SL0023 Start Date*: 2016-09-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SU...
    Medical condition: SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10040967 SLE LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002691-10 Sponsor Protocol Number: 700801 Start Date*: 2008-08-28
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Single-Blind, randomized, Phase III B Study in children aged 1-11 years to investigate the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines administered a...
    Medical condition: assess the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines in children aged 1-11 years
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-009324-36 Sponsor Protocol Number: B9371021_(Formerly_Baxter_700802) Start Date*: 2009-03-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: Active (prophylactic) immunization against TBE The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the fi...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000100-14 Sponsor Protocol Number: IC51- 302 Start Date*: 2005-09-08
    Sponsor Name:Intercell AG
    Full Title: Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV). Double blind, randomized, placebo controlled phase 3 study
    Medical condition: Japanese encephalitis (JE) is the most common viral encephalitis, with over 50,000 cases reported annually. It is a considerable public health problem for many Asian countries (WHO 1997). Close to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003201-81 Sponsor Protocol Number: GFVT01026904 (GACHE) Start Date*: 2006-12-20
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.
    Medical condition: Herpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002474-36 Sponsor Protocol Number: IC51-301 Start Date*: 2005-04-20
    Sponsor Name:Intercell AG
    Full Title: Observer blinded, randomized Phase III study to investigate the non-inferiority of IC51 (JE-PIV) vs. JE-VAX as vaccines for japanese encephalitis in healthy volunteers
    Medical condition: Japanese encephalitis (JE) is the most common viral encephalitis, with over 50,000 cases reported annually. It is a considerable public health problem for many Asian countries (WHO 1997). Close to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA